Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BZ 371B

Next Previous
X
Search
Drug Profile

BZ 371B

Alternative Names: BZ-371B

Latest Information Update: 05 Apr 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Biozeus
  • Class Antihypertensives; Peptides
  • Mechanism of Action Nitric oxide stimulants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adult respiratory distress syndrome; Pulmonary arterial hypertension

Most Recent Events

  • 05 Apr 2023 BZ 371B is still in preclinical trials for Pulmonary arterial hypertension in in Brazil (Biozeus pipeline, April 2023)
  • 30 Nov 2022 Biozeus Biopharmaceutical plans a early phase 1 trial for Acute respiratory distress syndrome (In adults, In the elderly) in Brazil (Inhalation) (NCT05384379)
  • 16 Sep 2021 Biozeus and Claritas Pharmaceuticals entered an agreement to develop BZ 371B for the treatment of Adult respiratory distress syndrome and Lung disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top